|Bid||0.4950 x 1100|
|Ask||0.5299 x 1000|
|Day's range||0.4917 - 0.5489|
|52-week range||0.2150 - 3.7200|
|Beta (5Y monthly)||-0.29|
|PE ratio (TTM)||N/A|
|Earnings date||19 May 2020 - 20 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.75|
NEW YORK, June 29, 2020 -- Life Sciences Investor Forum today announced that the presentations from the June 25th conference are now available for on-demand viewing at.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company anticipates that its current cash position will be sufficient to fund costs associated with conducting an additional Phase 3 pivotal trial for SB206 as a treatment for molluscum, or B-SIMPLE4 (Berdazimer Sodium In Molluscum Patients with Lesions). Since June 1, 2020, the Company has secured approximately $16.9 million in capital from the use of common stock purchase agreements with Aspire Capital Fund, LLC and the exercise of common stock warrants sold in its March 2020 public offering. The Company is targeting enrolling the first patient for B-SIMPLE4 in September 2020 and, if the trial is initiated on this timetable and not further impacted by the COVID-19 pandemic, top-line efficacy results would be targeted for late in the second quarter of 2021.
Novan, Inc. (“the Company” or “Novan”) (NOVN) today announced that Paula Brown Stafford, the Company’s President and Chief Executive Officer, will present a corporate overview at the Life Sciences Investor Forum on Thursday, June 25, 2020 at 2:00 p.m. Eastern. This will be a live, interactive online event where investors are invited to ask the company questions in real-time. The presentation and Q&A session will be webcast live and can be accessed through the Events page of the For Investors section of the Company's website at https://novan.gcs-web.com/events or at www.lifesciencesinvestorforum.com.